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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.009Apolipoprotein E4 (APOE4) genotype is the strongest genetic risk factor for late-onset Alzheimer disease
and confers a proinﬂammatory, neurotoxic phenotype to microglia. Here, we tested the hypothesis that
bone marrow cell APOE genotype modulates pathological progression in experimental Alzheimer disease.
We performed bone marrow transplants (BMT) from green ﬂuorescent proteineexpressing human APOE3/
3 or APOE4/4 donor mice into lethally irradiated 5-month-old APPswe/PS1DE9 mice. Eight months later,
APOE4/4 BMTerecipient APPswe/PS1DE9 mice had signiﬁcantly impaired spatial working memory and
increased detergent-soluble and plaque Ab compared with APOE3/3 BMTerecipient APPswe/PS1DE9
mice. BMT-derived microglia engraftment was signiﬁcantly reduced in APOE4/4 recipients, who also had
correspondingly less cerebral apoE. Gene expression analysis in cerebral cortex of APOE3/3 BMT recipients
showed reduced expression of tumor necrosis factor-a and macrophage migration inhibitory factor (both
neurotoxic cytokines) and elevated immunomodulatory IL-10 expression in APOE3/3 recipients compared
with those that received APOE4/4 bone marrow. This was not due to detectable APOE-speciﬁc differences
in expression of microglial major histocompatibility complex class II, C-C chemokine receptor (CCR)
type 1, CCR2, CX3C chemokine receptor 1 (CX3CR1), or C5a anaphylatoxin chemotactic receptor (C5aR).
Together, these ﬁndings suggest that BMT-derived APOE3-expressing cells are superior to those that
express APOE4 in their ability to mitigate the behavioral and neuropathological changes in experimental
Alzheimer disease. (Am J Pathol 2013, 183: 905e917; http://dx.doi.org/10.1016/j.ajpath.2013.05.009)Supported by NIH grants P50AG05136, T32AG000258 (E.C., E.J.M.),
and K01OD011072 (C.E.H.), and by the Nancy and Buster Alvord
Endowment.Humans uniquely have three different apolipoprotein E
(APOE ) alleles (ε2, ε3, and ε4). APOE4 is the single
greatest genetic risk factor for late-onset Alzheimer disease
(AD), and there is a gene dosage effect.1 However, genetic
association does not inform function/pathogenesis. Multiple
mechanisms have been postulated that predominantly focus
on production, metabolism, or clearance of amyloid-b (Ab)
and that are variably supported by multiple observations,
including: i) APOE genotype is strongly related to Ab levels
in brain and cerebrospinal ﬂuid of AD patients2,3; ii)
modulation of apolipoprotein E (apoE) protein levels in
brain results in alterations of Ab burden4,5; iii) Ab degra-
dation is at least partially apoE dependent6,7; and iv) Ab
clearance is differentially modulated by apoE isoforms, with
APOE4 mice exhibiting reduced central and peripheral Ab
clearance compared with APOE3 mice.8e10 Ab degradationstigative Pathology.
.and clearance is at least partially dependent on microglia,
the innate immune effector cells of the brain. Microglia have
migratory and phagocytic capacity, are increased in the
vicinity of Ab plaques, and phagocytose Ab.11e13 APOE
genotype modulates central nervous system innate immune
function in culture,14 including astrocyte and microglia
elaboration of cytokines and chemokines,15,16 microglia
production of reactive oxygen species,17 microglia-mediated
paracrine neurotoxicity,18 microglia migration,19 and other
functions.20 However, the speciﬁc contribution of microglial
APOE genotype to AD pathophysiology in vivo is largely
unknown.
Yang et alTo address this critical question and to test a potential
therapeutic application, we used the fact that bone marrow
transplantation (BMT) results in the gradual replacement of
endogenous (host) microglia (to the near exclusion of other
cell types) with microglia derived from donor marrow,
in both wild-type mice and transgenic mouse models of
AD.21e24 We used targeted-replacement (TR) APOE mice
homozygous for either the APOE3 or APOE4 gene inserted
into the mouse APOE regulatory elements25,26 that coex-
pressed green ﬂuorescent protein (GFP). We transplanted
whole bone marrow (BM) isolated from TR APOE3/3;GFP
or TR APOE4/4;GFP mice into lethally irradiated APPswe/
PS1DE9 mice to determine the speciﬁc role of microglial
APOE genotype in the pathological progression of AD.Materials and Methods
Animals
Transgenic Mice
BMT were performed in host double-transgenic APPswe/
PS1DE9 mice using TR APOE3/3;GFP or TR APOE4/
4;GFP mice as donors. The APPswe transgene encodes a
mouseehuman hybrid transgene containing the mouse se-
quence in the extracellular and intracellular regions and a
human sequence within the Ab domain with Swedish
mutations K594N and M595L. The PS1DE9 transgene
encodes exon-9edeleted human presenilin-1. Both trans-
genes are coexpressed under control of the mouse prion
promoter, with plaque deposition beginning at approxi-
mately 5 months of age.27,28 TR APOE mice are homozy-
gous for replacement of mouse apoE gene with the human
APOEε3 (APOE3) or APOEε4 (APOE4) allele backcrossed
onto a C57BL/6 genetic background,25,26 expressing human
isoforms apoE3 or apoE4 under control of mouse regulatory
elements. GFP mice (C57BL/6 background) were inter-
crossed with APOE3/3 or APOE4/4 animals to generate
homozygous GFP mice that were also homozygous APOE3/
3 or APOE4/4. GFP expression is under control of the b-
actin promoter and cytomegalovirus enhancer. All mouse
strains were purchased from the Jackson Laboratory (Bar
Harbor, ME) and maintained on a C57BL/6 background.
Mice were housed in standard laboratory conditions with
a strict 12-hour light/dark cycle and with free access to
mouse chow and water. All mice were used with approval
of the University of Washington Animal Care and Use
Committee.
Generation of Chimeric Mice
BMT was performed according to our previously published
protocols.24 Host APPswe/PS1DE9 double-transgenic mice
at 5 months of age received total-body 10.5-Gy single-dose
irradiation at approximately 2 Gy per minute from a cesium-
137 source (Model 81-14; JL Shepherd, San Fernando, CA).
BM cells were isolated from 8-week-old male APOE3/
3;GFP or APOE4/4;GFP transgenic mice by ﬂushing the906femur and tibias with RPMI media with 10% fetal bovine
serum. The samples were combined, passed through a 25-G
needle ﬁltered through a 70-mm nylon mesh, and centrifuged.
Erythrocytes were lysed in ammonium chloride potassium
buffer (Invitrogen, Carlsbad, CA), and the remaining leuko-
cytes were resuspended in sterile PBS at a concentration of
approximately 5  106 viable nucleated cells per 200 mL.
Irradiated APPswe/PS1DE9 mice received APOE3/3;GFP
(nZ 11) orAPOE4/4;GFP (nZ 8) bonemarrow cells (BMCs)
via retro-orbital venous plexus injections 1 day after total-body
irradiation and were housed in autoclaved cages. Chimeric
mice underwent behavioral testing 8 months after trans-
plantation and were then euthanized for tissue analysis.
Primary Cell Cultures
Microglia or astrocytes (APOE3/3 or APOE4/4) were iso-
lated and puriﬁed from neonatal mouse cortex following
established procedures29,30 and plated at 2.5  104 cells per
well in 96-well plates. Following 24 hours culture, the cells
were incubated in serum-free medium for an additional 18
hours. The conditioned medium was collected and apoE
protein levels were measured by an enzyme-linked immu-
nosorbent assay (ELISA) following the manufacturer’s
protocol (Mabtech AB, Cincinnati, OH). In brief, 100 mL of
conditioned medium (dilution 1:10) was loaded in 96-well
plates precoated with an anti-apoE antibody and incubated
for 1.5 hours at room temperature. The plates were rinsed in
PBS. A biotinylated detection antibody was added. After
1 additional hour incubation and rinsing, streptavidine
horseradish peroxidase was added for 1-hour incubation.
Tetramethylbenzidine substrate solution was added, fol-
lowed by stop solution. Optical density was read at a wave-
length of 450 nm.
Behavioral Analysis
Open Field
Locomotor activity and habituation to a novel environment
were measured using an open ﬁeld test. Mice of each group
were tested in the same session. Each mouse was placed in
the center of the open ﬁeld apparatus (40  40  30 cm;
San Diego Instruments, San Diego, CA). The bottom was
demarcated into a 5  5 grid making 25 equal-sized (8  8
cm) squares. Mice were allowed to explore the open ﬁeld
arena undisturbed for 5 minutes. This was repeated for 6
days. Videos were scored by an experimenter (C.E.H.) blind
to the study, for total distance traveled using AnyMaze
software version 4.2 (Stoelting Company, Wood Dale, IL).
A decrease in distance traveled over repeated trials is
indicative of recognition of and habituation to the novel
testing environment.
Barnes Maze
We used a modiﬁed Barnes maze protocol to assess
hippocampal-dependent spatial learning and memory. Theajp.amjpathol.org - The American Journal of Pathology
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1.0 m in diameter raised 75 cm off the ﬂoor containing 18
possible escape holes, one of which leads to a dark escape
box. Bright light and fan noise were used to increase
motivation for escape. Animals were trained to escape the
maze into the hidden box by allowing them to explore the
maze for 60 seconds and then placing them in the box with
a food pellet before any testing. Animals were then trained
over a 3-day acquisition phase to learn the location of the
escape box within the maze using spatial cues (three trials
per day with a 2-minute intertrial interval). Trials ended
when animals found the escape box or 300 seconds had
elapsed. After day 3, to increase the cognitive load on the
animals and engage working memory, the escape box was
moved to a different randomized location, and animals were
again given three trials to learn the new location (2-minute
intertrial interval) in a reversal learning scenario. Latency to
escape, distance traveled, and errors made (investigations
into decoy escape holes) were measured (AnyMaze). The
number of errors mice made in ﬁnding the escape box was
modeled as a Poisson distribution. Search strategies were
classiﬁed as random search, serial search, and spatial
search.31 An overall frequency was calculated for each type
of strategy for each mouse.
Tissue Collection and Processing
Animals were anesthetized with 2.5% tribromoethanol
(Avertin; Sigma-Aldrich, St. Louis, MO) 8 months post
transplantation. Blood was drawn via cardiac puncture and
processed for complete blood counts and ﬂow cytometry
before the mice were transcardially perfused with ice-cold
PBS. Brains were rapidly removed from the skulls and
divided by mid-sagittal section. One hemibrain was
dissected into anatomically distinct regions (including
rostral and caudal cerebral cortex, striatum, hippocampus,
cerebellum, thalamus/midbrain, and brainstem). The caudal
cortex fragment was immediately placed in cold HBSS and
processed for microglia isolation and quantitation of central
engraftment and microglia molecular phenotype by ﬂow
cytometry. The rostral cortex was divided into an RNA
fraction (>15 mg) and a protein fraction, and along with the
other regions, immediately ﬂash frozen in liquid nitrogen
and stored at 80C for mRNA or protein quantiﬁcation.
Total hippocampus from each mouse was required for
effective quantitation of Ab and apoE (Protein Extraction,
Ab, and apoE Quantiﬁcation), which thus precluded
hippocampal RNA isolation, and therefore, hippocampal
cytokine analysis. The contralateral hemibrain was post-
ﬁxed for 2 days in 4% paraformaldehyde (pH 7.6) and
then placed in PBS solution containing 30% (w/v) sucrose
for 2 days at 4C. The frozen brains were embedded in
optimal cutting temperature compound, frozen in liquid
isopentane, and then coronally sectioned in 40 mm incre-
ments using a cryostat (Leica CM3050; Leica, Wetzlar,
Germany). Slices were collected in cold cryoprotectantThe American Journal of Pathology - ajp.amjpathol.orgsolution [0.05 mol/L sodium phosphate buffer (pH 7.3),
30% ethylene glycol, and 20% glycerol] and stored at
20C until needed for immunostaining.
Microglia Isolation
Microglia/monocytes were isolated from brain homogenates
as described previously, with some modiﬁcations.32 Brieﬂy,
caudal cerebral cortex was dissociated by gentle homoge-
nization in HBSS. The cells were then incubated with HBSS
containing 15 U/mL papain, 100 mg/mL DNase, and 0.5
mmol/L EDTA (pH 7.4) for 20 minutes at 37C. The cell
suspension was passed through a 70-mm nylon cell strainer
and centrifuged at 300  g for 7 minutes. Supernatant was
removed, and cell pellets were resuspended in 70% isotonic
Percoll (GE Healthcare, Uppsala, Sweden). A discontinuous
Percoll density gradient was set up as follows: 70%, 35%,
and 0% isotonic Percoll. The gradient was centrifuged for
30 minutes at 1200  g. Mononuclear phagocytes were
collected from the interphase between the 70% and 35%
Percoll layers.33 Cells were washed and then resuspended in
HBSS for staining.
Flow Cytometry
Peripheral engraftment and differentiation ofGFPþ donorBM-
derived cells were assessed by ﬂow cytometry of peripheral
blood. Red blood cells were removed using lysis buffer
(Sigma-Aldrich). Cells were then washed several times in
buffer solution (HBSS containing 2% fetal bovine serum) and
incubated with antibodies on ice for 30 minutes. Cells were
ﬁxed with 1% paraformaldehyde and then analyzed using an
LSR II ﬂow cytoﬂuorometer (BD Biosciences, Franklin lakes,
NJ). Identically processed blood from GFP and wild-type
mice was used as controls. Peripheral (blood) engraftment
was determined as a percentage of GFPþ cells divided by the
total number of nucleated cells. Multilineage differentiation
of donor BMCs was determined by staining with eFluor
450econjugated CD3 (T cells), PerCP-Cy5.5econjugated
CD19 (B cells), allophycocyanin (APC)-conjugated Gr-1
(neutrophils), and phycoerythrin (PE)-conjugated CD11b
(monocytes/macrophages) antibodies (eBioscience, San
Diego, CA). Appropriately labeled IgG isotype control
antibodies were used as negative controls.
For central nervous system (CNS) engraftment, ﬂow
cytometric analysis was performed on mononuclear cells
(vide infra) isolated from cerebral cortex. The cells were
washed and then stained with PE-Cy7econjugated CD11b
and Alexa Fluor 700econjugated CD45 antibodies for 60
minutes. The cell suspension was analyzed to identify the
population of CD11bþCD45low microglia.34e36 Central
(cerebral cortex) engraftment of BM-derived microglia was
determined by dividing the CD11bþCD45lowGFPþ cell
population by total CD11bþCD45low microglia. The
assessment of cell-surface protein expression was performed
using eFluor 450econjugated major histocompatibility907
Yang et alcomplex (MHC) class II (eBioscience), APC-conjugated C-
C chemokine receptor type 1 (CCR1), PE-conjugated CCR2
(R&D Systems, Minneapolis, MN), or Alexa Fluor 647e
conjugated C5a anaphylatoxin chemotactic receptor (C5aR,
alias CD88) (AbD Serotec, Kidlington, UK) antibody. After
washing, the cells were incubated with the ﬂuorescent-
labeled primary antibody or IgG isotype control for 60
minutes at 4C. For CX3C chemokine receptor 1 (CX3CR1)
detection, washed cells were ﬁrst incubated with mono-
clonal antibody anti-CX3CR1 (Abcam, Cambridge, MA) or
IgG isotype control for 60 minutes on ice. After washing,
cells were incubated for 60 minutes with a PerCP-
conjugated anti-rat polyclonal antibody (Jackson Immu-
noresearch, West Grove, PA). The expression of MHC class
II, CCR2, and CX3CR1 was assessed as mean ﬂuorescence
intensity in GFPþ and GFP microglia populations. All
ﬂow cytometry experiments were performed using a four-
laser and 12-color ﬂow cytoﬂuorometer LSR II (BD
Biosciences). Data were analyzed with FlowJo software
version 7.2.2 (Tree Star, Ashland, OR).
Immunoﬂuorescence and Stereological Analysis
Every sixth coronal section was used for immunostains and
unbiased stereological methods (13 months of age, nZ 8 to
11 per group). Immunoﬂuorescence staining was performed
according to previously published protocols.24 Primary
antibodies included antieIba-1 (dilution 1:500; Wako,
Richmond, VA) and anti-Ab 1-16 peptides (dilution 1:1000;
6E10;Covance, Princeton, NJ); species-appropriate secondary
antibodies were conjugated to Cy3 (dilution 1:400; Jackson
Immunoresearch). Prolong-gold anti-fade with DAPI (Invi-
trogen) was used for coverslipping and nuclear counterstain.
All images were captured using an FV1000 laser scanning
confocal microscope (Olympus, Center Valley, PA).
To quantify ionized calcium binding adaptor molecule
1epositive (Iba-1þ) microglia and BM-derived mononuclear
cells (GFPþ), sections were analyzed using unbiased
stereological cell quantiﬁcation using systematic random
sampling. Every sixth brain section (240 mm apart) was
analyzed at 400 magniﬁcation using a Nikon inverted
ﬂuorescence microscope (Melville, NY) and Stereo Investi-
gator software version 7.52 (MBF Bioscience, Williston,
VT). An optical fractionator was used with a counting frame
measuring 150 mm  150 mm applied every 500 mm in
hippocampus and every 750 mm in cortex. Cells were
assessed as Iba-1þ, GFPþ, or Iba-1þ and GFPþ double
immunopositive. All analysis was performed by operators
blinded to experimental conditions (N.L.J. and Y.Y.).
Immunohistochemistry and Plaque Assessment
To assess Ab plaques, every sixth section (average, 15 per
mouse) was processed for immunohistochemistry using
a rabbit polyclonal antiepan Ab antibody (dilution 1:750;
Invitrogen) according to our previously published protocol.24908Brain sections were immersed in Tris-buffered saline (50
mmol/L Tris, 138 mmol/L NaCl, 2.7 mmol/L KCl). Endog-
enous peroxidase in tissue was quenched by treating with
30% methanol and 1% H2O2 in PBS for 2 minutes at room
temperature. Nonspeciﬁc background staining was blocked
by incubation in 10% donkey serum, 2% bovine serum
albumin with 0.5% Triton X-100, and 0.1% azide in Tris-
buffered saline for 3 hours. Sections were then incubated
with primary antibody overnight at 4C, rinsed three times
with Tris-buffered saline, and then incubated with bio-
tinylated secondary antibody followed by ABC kit reagent
(Vector Laboratories, Burlingame, CA) for 2 hours each.
Finally, the sections were incubated for exactly 3 minutes
with diaminobenzidine (DAB) (Sigma-Aldrich). After
washing, the sections were mounted on slides, dehydrated in
a series of graded ethanol, cleared with Citri-Solv, and then
coverslipped with Permount mounting medium (Fisher
Scientiﬁc, Pittsburgh, PA).
Stained sections were photographed (Nikon Super Cool-
scan 4000 ED), and the digital images were analyzed sepa-
rately for cerebral cortex and hippocampus using ImageJ
software version 1.46r (NIH, Bethesda, MD). Total area of
immunoreactivity was determined using a standardized
histogram-based threshold technique. The percent area
occupied by Ab-immunoreactive plaques, as well as the
plaque size and numbers, was averaged over all sections for
each mouse, and averaged values from each mouse were used
in statistical analysis. The operator (J.F.H.) was blinded to
experimental conditions.
Protein Extraction, Ab, and apoE Quantiﬁcation
Proteins from rostral cortex and total hippocampus were
extracted using a modiﬁed version of previously published
procedures.24,37,38 All manipulations were performed on ice
to minimize protein degradation. Tissue was weighed and
placed in an Eppendorf tube containing Tris-HCl buffer [20
mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L
phenylmethylsulfonyl ﬂuoride, and protease cocktail inhib-
itor tablet (Roche, San Francisco, CA)] at a concentration
of 10 mL/mg and was then sonicated on ice three times for
10 seconds at a time. After 30 minutes centrifugation at
30,000  g at 4C, the supernatant (soluble fraction) was
collected and frozen at 80C. The insoluble pellet was
resuspended in 5 mol/L guanidine-HCl buffer with the same
volume as Tris-HCl buffer followed by 30 minutes centri-
fugation at 30,000 g at 4C. The supernatant (insoluble
fraction) was collected and frozen at 80C. Quantiﬁcation
of soluble and insoluble Ab40 and Ab42 was performed
using human Luminex kits (Invitrogen) according to the
manufacturer’s protocol. Tris-HCl soluble cortical and
hippocampal fractions from chimeric mice were generated
as described above and assayed for apoE using a commer-
cially available human apoE ELISA per the manufacturer’s
protocol (#3712-1H-6; Mabtech AB). The monoclonal
capture antibody shows cross-reactivity with mouse apoE.ajp.amjpathol.org - The American Journal of Pathology
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Total RNA was extracted from rostral cortex of chimeric
mice at 8 months after BMT using the RNeasy kit (Qiagen,
Valencia, CA) according to the manufacturer’s suggestions.
Each cohort of 8 to 11 mice was analyzed for mRNA levels
of chemokine ligand 2 (CCL2), chemokine (C-X3-C motif)
ligand 1 (CX3CL1), IL-6, tumor necrosis factor-a (TNF-a),
IL-4, IL-10, macrophage migration inhibitory factor (MIF),
and CCL8 with real-time quantitative PCR (qPCR). One
microgram of total RNA was reverse-transcribed using
a RETROscript kit (Ambion, Austin, TX). The cDNA
synthesized from total RNA was diluted 10-fold with
DNase-free water, and each cDNA sample was indepen-
dently tested three times. Transcript quantities were assayed
by TaqMan gene expression assay (Applied Biosystems,
Foster City, CA): CCL2 (ID Mm00441242_m1), CX3CL1
(ID Mm00436454_m1), IL-6 (ID Mm00446190_m1), TNF-
a (ID Mm00443260_g1), IL-4 (ID Mm00445259_m1), IL-
10 (ID Mm00439614_m1), MIF (ID Mm01611157_gH),
and CCL8 (ID Mm01297183_m1) were assayed in a model
7300 real-time PCR system (Applied Biosystems). Cycling
conditions of the real-time PCR were 95C for 20 seconds,
40 cycles of 95C for 1 second, and 60C for 20 seconds.
Mouse 18s ribosomal RNA (ID Mm03928990_g1) expres-
sion was used as an endogenous control. qPCR was per-
formed according to the guidelines provided by Applied
Biosystems. The comparative cycle threshold (CT) method
(DDCT quantitation) was used to assess the difference
between samples. Quantitative data analysis followed the
suggestions of the manufacturer.
Statistical Analysis
Results are expressed as means  SEM. Statistical analysis
was performed by the unpaired Student t-test or one- or two-
way analysis of variance as indicated. Post hoc testing used
the Bonferroni method. Statistical signiﬁcance was assumed
if P < 0.05. All statistical analyses were performed using
GraphPad Prism software version 5.03 (San Diego, CA).
Results
Generation of TR APOE3/3;GFP and TR APOE4/4;GFP
APPswe/PS1DE9 Chimeras
BMfromTRAPOE3/3;GFPor TRAPOE4/4;GFP donormice
was transplanted into 5-month-oldAPPswe/PS1DE9 recipient
mice 24 hours after myeloablative (10.5 Gy) whole-body
irradiation. The resulting APOE3/3;GFP and APOE4/4;GFP
APPswe/PS1DE9 chimeras underwent behavioral testing at 8
months post-BMT and were then euthanized. Blood was
collected by cardiac puncture at the time of sacriﬁce, and
complete blood counts with differentials were performed;
white blood cell, red blood cell, and platelet counts did not
differ between groups (Supplemental Figure S1, AeC).The American Journal of Pathology - ajp.amjpathol.orgMultilineage differentiation of hematopoietic stem cells was
within the normal range, with no signiﬁcant differences
between groups (Supplemental Figure S1D).
Hematopoietic Engraftment by APOE3/3 or APOE4/4
Donor Cells
To determine BM engraftment, GFPþ cells in the chimeras
were analyzed by ﬂow cytometry. As expected, almost all
blood mononuclear cells were GFPþ, and there was no
difference in total peripheral engraftment between donor
genotypes (Figure 1A). Using lineage-speciﬁc antibodies, we
next analyzed the mononuclear cell composition to compare
differentiation into hematopoietic lineages in hematopoietic
stem cells. We found no differential inﬂuence of APOE on the
proportions of T and B lymphocytes and neutrophils
(Figure 1B). Interestingly, although differential blood counts
revealed no differences in total monocytes (Supplemental
Figure S1D), ﬂow cytometry of peripheral blood showed
APOE4/4 BMT gave rise to fewer CD11bþ monocytes/
macrophages than did APOE3/3BMT (P< 0.05) (Figure 1B),
suggesting effects of APOE on monocyte molecular pheno-
type in the periphery. Representative ﬂow cytometric contours
for each hematopoietic lineage are shown in Figure 1C.
Increased CNS Microglia/Monocyte Engraftment by
APOE3/3 versus APOE4/4 Donor Cells
We next determined microglia density and CNS engraftment
in both chimeras. Mononuclear cells were isolated for ﬂow
cytometry from cerebral cortex and were then probed for
microglia, which, unlike peripheral monocytes, are CD11b-
positive (CD11bþ) and CD45-low expressing (CD45low)
cells.39 Although almost half of the CD11bþCD45low cells
were BMT derived (GFPþ) in APOE3/3 recipients, less than
a third of microglia in APOE4/4 recipients were derived
from the donor transplant (P < 0.01) (Figure 2A). Flow
cytometric contours from representative mice are presented
in Figure 2B.
To further quantitate APOE genotype effects on BMT-
derived monocyte/microglia engraftment and to evaluate
microglia morphology, we analyzed hippocampus and cere-
bral cortex from the contralateral hemisphere using immuno-
ﬂuorescence histology. BMT-derived cells were identiﬁed by
strong GFP autoﬂuorescence in both groups, and on the basis
of Iba-1 immunopositivity, were almost uniformly microglia
(Figure 3A). Donor and host microglia in both groups were
mostly classically ramiﬁed, with some Iba-1þ cells showing
blunted processes and enlarged somas. However, macro-
phage/amoeboid morphology was not identiﬁed in Iba-1þ
cells from either group. Unbiased stereological analysis
revealed signiﬁcantly increased donor-derived microglia in
APOE3/3 compared to APOE4/4 recipients in cerebral cortex
(55.2  4.0% APOE3/3 versus 39.3  5.6% APOE4/4; P <
0.05) and in hippocampus (63.0  3.9% APOE3/3 versus
44.9  5.0% APOE4/4; P < 0.05) (Figure 3B). Overall,909
Figure 1 Peripheral (blood) engraftment and hematopoietic reconsti-
tution in BMT recipients. A: Percent peripheral engraftment was calculated
by comparing GFPþ leukocytes to total leukocytes using ﬂow cytometry, and
revealed nearly complete peripheral engraftment with no signiﬁcant donor
genotype differences detected. B: Flow cytometric analysis of peripheral
blood for hematopoietic lineage differentiation of GFPþ BMT-derived cells.
GFP ﬂuorescence was measured in T lymphocytes, B lymphocytes, neutro-
phils, and monocytes/macrophages, and revealed a signiﬁcant inﬂuence of
donor APOE genotype on the percentage of donor-derived monocytes. *P <
0.05, two-way analysis of variance analysis using the Bonferroni post hoc
test. All results are expressed as means  SEM, nZ 8 to 11. C: Flow cyto-
metric analysis of peripheral blood of representative mice stained with
antibodies to the ﬂuorophore-conjugated T-cell marker CD3, B-cell marker
CD19, neutrophil marker Gr-1, and CD11b (to stain the monocytes and
macrophages). GFP intensity (marking donor cells) is plotted on the x axis,
and the intensity of the stain with lineage-speciﬁc markers of hematopoietic
differentiation is plotted on the y axis. Positive graph shows the pattern of
a nontransplanted GFP mouse (GFP No Tx). Negative graph (GFP No Tx, inset)
shows autoﬂuorescence pattern of a nontransplanted wild-type mouse; iso
graph (APOE3/3;GFP/AD, inset) shows isotype-matched nonspeciﬁc
antibody staining of the transplanted mouse.
Figure 2 Flow cytometric analysis of cerebral cortical engraftment of BMT-
derived microglia. Mononuclear cells were isolated (dissociation with Percoll
gradient) from rapidly dissected cerebral cortex from APPswe/PS1DE9 mice
transplanted with APOE3/3;GFP or APOE4/4;GFP BMCs 8 months post-
transplantation after transcardial perfusion with ice-cold PBS. A: Engraftment
of GFPþCD11bþCD45low microglia was increased in APOE3/3;GFP compared with
APOE4/4;GFP recipient APPswe/PS1DE9 mice. **P < 0.01, unpaired Student’s
t-test.B: Representativeﬂowcytometric contoursof GFPﬂuorescence (x axis) in
CD11bþCD45low gate (y axis) are shown for population of host (GFP) versus
donor (GFPþ) microglia. Negative graph (APOE3/3/AD, inset) shows the
pattern of a nontransplanted wild-type mouse. Positive graph (APOE4/4/AD,
inset) shows the pattern of a nontransplanted GFP mouse.
Yang et alcerebral cortical and hippocampal microglia densities
(expressed as Iba-1þ cells per mm3) were not signiﬁcantly
different between the two groups in the cortex or hippo-
campus, and there was no signiﬁcant APOE effect on total
microglia density between BM recipients (Figure 3C). Taken
together, ﬂow cytometric and stereological data suggest that
APOE3/3 donor monocytes are more efﬁciently engrafted in
the brain than APOE4/4 donor monocytes.
Increased CNS apoE Concentration in APOE3/3
Recipient Mice
Because APOE3/3 recipients had increased densities of
BMT-derived microglia, we determined whether BMT
using donor marrow from mice expressing human APOE3910or APOE4 might modulate brain apoE levels in cerebral
cortex and hippocampus. APOE3/3 transplantation resulted
in 45  8% greater cerebral cortical apoE protein levels than
did APOE4/4 (P < 0.001) (Figure 4). A similar change
(40  11% greater apoE) was observed in the hippocampus
of APOE3/3 recipients (P < 0.01) (Figure 4).
Others have demonstrated in primary cultures of mixed
glia that microglia, especially under conditions of innate
immune activation, contribute a substantial proportion of
secreted apoE.40 We further pursued apoE isoform glial
secretion in primary cultures of microglia or astrocytes
prepared from APOE mice (Figure 5). Under basal culture
conditions, which likely represent at least mild activation
compared to in vivo, APOE3/3 primary astrocyte cultures
secreted more apoE than did APOE4/4 astrocytes. Primary
microglia cultures from the same mice secreted comparable
amounts of apoE as astrocytes but with the opposite isoform-
speciﬁc relationship: APOE4/4 secretion was greater than
that of APOE3/3 (Figure 5). Importantly, two-way analysis of
variance for these data showed a signiﬁcant interaction
between APOE and glial cell type (P < 0.01).
Improved Habituation and Spatial Working Memory in
APOE3/3;GFP Recipients
Open ﬁeld and Barnes maze behavior test data were
analyzed for APOE-dependent effects. Nontransplantedajp.amjpathol.org - The American Journal of Pathology
Figure 3 Cortex and hippocampal microglia in BMT-recipient mice.
Iba-1 immunostaining was performed on 40-mm sections from 13-month-
old APPswe/PS1DE9 mice sacriﬁced 8 months post-BMT. A: Iba-1 immu-
noreactivity (red) for microglia shows no clear difference in total microglia
between groups and highlights predominantly ramiﬁed morphology in both
groups. Fluorescence microscopy reveals an increased density of GFPþ cells
(GFP, green, inset) in the cortex of APOE3/3;GFP/APPswe/PS1DE9 mice
compared with APOE4/4;GFP/ APPswe/PS1DE9 mice. Merged images
conﬁrm that GFPþ cells are also uniformly Iba-1þ and therefore of donor
origin, whereas others represent endogenous microglia and only express
Iba-1. Scale bars: 50 mm; 10 mm (insets). B: Unbiased stereological
analysis of BMT-derived microglia engraftment in the cortex and hippo-
campus of chimeric mice reveals proportionately increased engraftment in
APOE3/3;GFP recipients compared with APOE4/4;GFP recipients. *P < 0.05,
unpaired Student t-test. C: Quantitative analysis of microglia cell density
(total Iba-1þ microglia/mm3) in the cortex and hippocampus of chimeric
mice shows no evidence of APOE genotype effect on total microglia. Error
bars show the means  SEM, n Z 8 to 10.
Figure 4 Effect of donor APOE genotype on cerebral apoE concentra-
tion. Cortex and hippocampus Tris-HCl buffer lysates from 13-month-old
APPswe/PS1DE9 mice that received BMT from APOE3/3;GFP or APOE4/4;GFP
donor mice 8 months before sacriﬁce were subjected to ELISA for apoE.
There was signiﬁcantly increased apoE concentration in mice that received
APOE3/3;GFP BMT compared with APOE4/4;GFP recipients in both cortex
and hippocampus. **P < 0.01, ***P < 0.001, Student’s t-test.
Figure 5 Primary cultures of mouse astrocytes or microglia were prepared
from neonatal TR APOE3/3 (white bars) or APOE4/4 (black bars) mice and
plated at 2.5  104 cells per well in 96-well plates. Following 24 hours in
culture, the medium was replaced with serum-free medium. After 18 hours in
culture, the conditioned medium was assayed for apoE concentration by
ELISA. Two-way analysis of variance (df 1,1,40) had P < 0.01 for interaction
between APOE and glial cell type, but was not signiﬁcant for either APOE or
glial cell type. *P < 0.05 for APOE3/3 versus APOE4/4 in astrocyte and in
microglia conditioned medium, Bonferroni-corrected post-test comparisons.
APOE BMT in an AD ModelAPPswe/PS1DE9 mice demonstrated behavior consistent
with that previously reported by others in both tests.41,42
APOE3/3 mice showed habituation to a novel environment
as seen by a progressive reduction in total distance traveled
over successive days (P < 0.05) (Figure 6A). By contrast,
APOE4/4 mice showed no signiﬁcant reduction in distance
traveled over successive days. There was no signiﬁcant
difference (P> 0.05) in baseline locomotor function between
the two groups, nor were there any signiﬁcant differences
(P > 0.05) in the acquisition phase of the Barnes maze test;The American Journal of Pathology - ajp.amjpathol.orghowever, reversal learning was signiﬁcantly (P < 0.05)
preserved in APOE3/3 BM recipients compared with
APOE4/4 recipients. APOE3/3 mice exhibited reduced
distance traveled (P < 0.01) (Figure 6, B and C), shorter
escape latency (P< 0.01) (Figure 6D), and fewer errors (P<
0.01) (Figure 6E) than APOE4/4mice. Characterization of
search strategy in the Barnes maze can provide insight into
functional impairment.31 Analysis of videos from each
mouse for each trial revealed that the APOE3/3 BM recipi-
ents used a predominantly (33%) spatial search strategy,
whereas the APOE4/4 group used a predominantly (42%)
random one (Figure 6F). These APOE4/4 recipients only
used a spatial or serial search strategy 16% of the time,
whereas APOE3/3 recipients used one of these strategies
50% of the time (Figure 6F). These data demonstrate better
spatial working memory in APPswe/PS1DE9 recipients of
APOE3/3 versus APOE4/4BMT. Given these APOE-speciﬁc
differences in behavior, we next explored cellular and
biochemical changes in the brains of these mice.911
Figure 6 APOE3/3;GFP BMT mitigates behavioral deﬁcits in APPswe/PS1DE9 mice. A: Open ﬁeld: as a proxy for cognitive function, habituation to an open
ﬁeld was analyzed by determining whether total distance traveled decreased as a function of time (trial day). Linear regressions were performed. Slopes signiﬁcantly
different from zero were interpreted as normal cognition, because distance is expected to decrease with subsequent testing in cognitively normal animals. *P< 0.05.
Results are expressed as means  SEM, nZ 8 to 10. BeE: Barnes maze: 13-month-old APOE3/3;GFP BMTerecipient APPswe/PS1DE9 mice exhibited preserved
cognitive function compared with APPswe/PS1DE9 mice that received APOE4/4;GFP BMT. After a 3-day training session, the escape location was switched and the
mice tested over three trials to ﬁnd the new location. B: The track plots represent paths traveled during challenge trials of the chimeric mice. APOE3/3;GFP BMT
recipients traveled a shorter distance (C), required less time (D), and made fewer errors (E) than APOE4/4;GFP BMT recipients. *P< 0.05, **P< 0.01, Student t-test.
All results are expressed as means SEM. F: Videos of each mouse from each challenge trial were scored for the percent time spent with speciﬁc search strategies
revealing thatAPOE3/3;GFPBMT recipients used serial (yellow) and spatial (red) search strategies 50%of the time, compared to 16% for APOE4/4;GFP BMT recipients.
Yang et alReduced CNS Ab in APOE3/3;GFP-Recipient APPswe/
PS1DE9 Mice
One possible cause of preserved behavioral performance in
APOE3/3 than APOE4/4 BM recipients is suppression of
Ab accumulation in brain as a result of more efﬁcient
engraftment of cerebral cortex and hippocampus. To test
this possibility, we ﬁrst quantiﬁed Ab plaque burden (total
area occupied by plaque, plaque frequency, and mean pla-
que size) in hippocampus and cortex from both groups using
a standard thresholding technique on coronal sections that
had been immunohistochemically stained with a pan-Ab
antibody (Figure 7A). Total area occupied by Ab plaques912(2.9% APOE3/3 versus 3.9% APOE4/4; P < 0.05) and plaque
frequency (856/mm2 APOE3/3 versus 1113/mm2 APOE4/4;
P < 0.05) were signiﬁcantly reduced in the hippocampi of the
APOE3/3 group compared to the APOE4/4 group (Figure 7B).
APOE genotype effects were less apparent in cerebral cortex,
where plaque frequency (1822/mm2 APOE3/3 versus 2027/
mm2 APOE4/4; P < 0.05) was lower in APOE3/3 recipients,
but there was no signiﬁcant effect of donor APOE genotype
on total area occupied by plaques (Figure 7B). Average pla-
que size was not affected by donor genotype in either cortex
or hippocampus (Supplemental Figure S2, A and B). When
we examined adjacent sections with immunoﬂuorescence, we
found qualitatively more BM-derived cells in association withajp.amjpathol.org - The American Journal of Pathology
Figure 7 Quantiﬁcation of Ab plaque burden in APOE3/3;GFP versus APOE4/4;GFP-recipient APPswe/PS1DE9 mice. A: Immunohistochemical stains for Ab
in hippocampus from 13-month-old chimeric mice 8 months post-transplantation reveal reduced plaque in APOE3/3;GFP-recipient mice compared with APOE4/
4;GFP recipients. Scale bar Z 500 mm. B: Quantitative analysis using standard thresholding techniques reveals signiﬁcantly reduced area plaque density in
cortex and in total area occupied by plaque as well as plaque density in hippocampus in APOE3/3;GFP-recipient mice compared with APOE4/4;GFP recipients.
*P < 0.05, unpaired Student’s t-test. Data are means  SEM, nZ 8 to 11. C: Confocal image analysis of representative brain sections stained for Ab (red), GFP
ﬂuorescence (green), and DAPI (blue) reveal increased plaque-associated BMT-derived cells in APPswe/PS1DE9 mice transplanted with APOE3/3;GFP (inset)
versus APOE4/4;GFP BM (inset). Scale bars: 20 mm; 50 mm (insets).
APOE BMT in an AD ModelAb plaques in the hippocampi of APOE3/3 chimeras com-
pared with APOE4/4 (Figure 7C). In both groups, GFPþ cells
around plaques exhibited a less ramiﬁed morphology, with
blunted processes extending around and into the immuno-
positive amyloid core (Figure 7C).
We further characterized Ab burden in these mice using
sequential extraction of Tris/HCl buffere and guanidine-
soluble Ab. We found no signiﬁcant differences in Tris/HCl
bufferesoluble Ab40 or Ab42 between the two groups in
cerebral cortex or hippocampus (Supplemental Figure S3, A
and B). However, APOE3/3 BMT recipients contained
signiﬁcantly less guanidine-soluble Ab40 in cerebral cortex
and hippocampus compared with mice that received APOE4/4The American Journal of Pathology - ajp.amjpathol.org(P< 0.05) (Figure 8, A and B). There was no signiﬁcant effect
of donor APOE genotype on levels of guanidine-soluble Ab42
in cortex or hippocampus (Figure 8, A and B).
CNS Immune Modulation
TNF-a and MIF, cytokines that are elevated in patients with
AD, and key activators of microglia-mediated neurotoxicity,
were measured in cerebral cortex using real-time PCR. Both
TNF-a and MIF concentrations were signiﬁcantly elevated
inAPOE4/4 compared toAPOE3/3 recipients (Figure 9A). By
contrast, levels of IL-10, a cytokine that suppresses the actions
of proinﬂammatory cytokine production and is associated913
Figure 8 A and B: Quantiﬁcation of Ab species in BMT-recipient mice. A
portion of cerebral cortex and whole hippocampus from 13-month-old BMT-
recipient mice euthanized 8 months post-transplant and then perfused with
ice-cold PBS were homogenized and sequentially dissolved in Tris-HCl buffer
followed by 5mol/L guanidine, and the lysateswere then subjected to Luminex
assay for Ab species. Lysates in Tris-HCl buffer showed no donor APOE geno-
typeedependent differences in Ab concentration (Supplemental Figure S3),
but there was a signiﬁcant reduction in cortical (A) and hippocampal (B)
guanidine soluble (insoluble) Ab40 in APOE3/3;GFP BMT recipients compared
with APOE4/4;GFP recipients. *P < 0.05, unpaired Student’s t-test. No
signiﬁcant differences were identiﬁed in Ab42 levels in cortex or hippocampus
between different donor APOE genotypes. Data are means SEM, nZ 8 to 11.
Yang et alwith a pro-phagocytic phenotype,43,44 were lower in the
APOE4/4 group (Figure 9A). Donor APOE genotype did not
promote differences in cerebral cortex expression of IL-6,
IL-4, CCL2, CX3CL1, and CCL8 (Supplemental Figure S4).
MHC class II has been shown to be increased in BMT-
derived microglia, which we conﬁrmed in both APOE3/3-
and APOE4/4-derived microglia in this study in comparison
with endogenous cells (P< 0.01 for APOE3/3microglia and
P < 0.05 for APOE4/4 microglia) (Figure 9B). However,
there was no effect of donorAPOE genotype onMHC class II
expression. We found that chemokine receptor CCR2 was
up-regulated in donor-derived microglia compared with
endogenous microglia (P< 0.05) (Figure 9B), but again, we
found no effect of APOE. Microglia origin (host versus
donor) and genotype (APOE3 versus APOE4) had no effect
on expression of microglial complement receptor C5a or
chemokine receptors CX3CR1 or CCR1 (Supplemental
Figure S5). Overall, these results indicate that APOE4/4
BMT resulted in a more proinﬂammatory state in cerebral
cortex and hippocampus than did APOE3/3.
Discussion
Here, we tested the hypothesis that BMT with APOE3- or
APOE4-expressing donor cells has both behavioral and
neuropathological consequences in a mouse model of AD.914Following previous work that optimized the age and dura-
tion of BMT,24 we performed our experiments using
APOE3/3;GFP or APOE4/4;GFP donor cells and 5-month-
old APPswe/PS1DE9 transgenic recipient mice 24 hours
following myeloablative BMT with 10.5-Gy whole-body
irradiation, and concluded our experiments at 8 months
post-BMT (13 months of age). Using GFP allowed us to
focus exclusively on apoE isoforms derived from BM donor
cells because other cellular sources of mouse apoE remained
intact in the recipient mice. We selected this approach,
rather than using APOE-null mice, to better model the
potential clinical situation if this approach were to prove to
be successful in experimental models.
We demonstrated that hematological engraftment by
APOE3/3 or APOE4/4 BM was nearly complete and that
blood cell differentiation, including monocytes, was similar
for these two groups except for proportionately greater
numbers of CD11b monocyte/macrophage lineage cells in
APOE3/3 recipients. Perhaps related, the total number of
microglia/monocytes in cerebral cortex and hippocampus
were not signiﬁcantly changed by BMT, but the replace-
ment of resident cells was approximately half with APOE3/3
BM compared to approximately one-third with APOE4/4
BM. As with our previous experiments, we observed only
BM-derived microglia/monocytes in brain parenchyma; no
astrocytes or neurons were observed. Importantly, APOE3/3
recipients also had improved habituation and spatial
working memory compared to APOE4/4 recipients. Finally
we pursued several, potentially interrelated, mechanisms of
action and showed that APOE3/3 recipients had increased
apoE tissue concentration, reduced burden of some forms of
cerebral Ab, and a relatively anti-inﬂammatory environment
compared to APOE4/4 recipients.
The BMT strategy used necessarily constrained our
experimental design and thus ﬁnal interpretation, rendering
precise mechanistic interpretation difﬁcult. Indeed, the
APOE3/3-speciﬁc effects observed here could be mediated
by differences in apoE concentration, intrinsic isoform-
speciﬁc activities, relevant APOE genotypeedependent
phenotypic differences in microglia, or some complex
combination of these or other unsuspected interactions.
Importantly, direct and indirect modulation of brain apoE
has been shown to inﬂuence Ab trafﬁcking, cerebral Ab
concentration and plaque density, and local innate immune
responses in a variety of mouse models.4,5,8e10 Because
reduction of Ab plaque density and Ab tissue concentration
correlate with improved performance on behavioral tests in
mice, one interpretation of our results is that BMT with
APOE3/3 led to increased cerebral apoE concentration,
resulting in reduced Ab accumulation and suppressed neu-
roinﬂammation that together improved behavioral test
performance. How might BMT with APOE3/3 have selec-
tively increased cerebral cortical and hippocampal concen-
tration of apoE? Because virtually all donor cells in
cerebrum were microglia/monocytes, one possibility is that
engrafted APOE3/3 microglia secreted more apoE. Indeed,ajp.amjpathol.org - The American Journal of Pathology
Figure 9 Alterations in innate immune molecular phenotype in BMT-recipient mice. A: Cortical tissue from 13-month-old mice that received BMT 8 months
before sacriﬁce and were transcardially perfused with ice-cold PBS was ﬂash frozen at the time of euthanasia, and RNA was isolated for qPCR analysis of inﬂammatory
markers. Qualitative quantiﬁcation was performed for each transcript. A decrease of mRNA levels in TNF-a and MIF and an increase in IL-10 mRNA levels was found in
mice transplanted with APOE3/3;GFP BMCs compared with the chimeras that received APOE4/4;GFP BMCs. *P < 0.05, unpaired Student’s t-test. All results are
expressed as means  SEM, nZ 7 to 11. B: Mononuclear cells were isolated from cortex adjacent to that used for qPCR in the same mice. The cells (isolated with
Percoll gradient) were resuspended and subjected to ﬂow cytometric analysis for identiﬁcation of donor (GFPþCD11bþCD45low) and host (GFPCD11bþCD45low)
microglial expression of innate immune effector molecules. Comparison of mean ﬂuorescence intensity (MFI) in endogenous (GFP, grey bars) and donor (GFPþ,
black bars) microglia for MHC class II and CCR2 revealed a signiﬁcant reduction in both cell-surface proteins in endogenous versus donor cells, but no effect of donor
APOE genotype. **P < 0.01, *P < 0.05, two-way analysis of variance analysis was performed using the Bonferroni post hoc test. MFIs were normalized to GFP
microglia from APOE3/3;GFP/APPswe/PS1DE9 chimeras for every phenotype. All results are expressed as means  SEM, nZ 8 to 11.
APOE BMT in an AD Modelnumerous studies have been performed to assess apoE
protein levels in human serum,45 cerebrospinal ﬂuid,46 and
brain47,48; all have shown greater apoE concentration in the
APOE3 compared to the APOE4 background. Although our
results from primary astrocytes were consonant with these
data, primary microglia showed the opposite relationship to
APOE with greater secretion by APOE4/4 than APOE3/3
microglia, making this potential explanation for increased
apoE in APOE3/3 recipients unlikely. Further complicating
such assessments is the potential for subtle interaction
between donor-derived and resident host microglial pop-
ulations resulting from incomplete central engraftment. In
addition, whereas donor-derived microglia express human
apoE isoforms, the AD host mice themselves express mouse
apoE, creating a complex chimeric environment, the effects
of which remain difﬁcult to assess. Alternatively, the APOE
genotypeedependent differential engraftment observed may
have inﬂuenced Ab deposition independent of brain apoE
levels or in concert with the observed differences. Another
potential explanation was that myeloablative BMT had
permanently damaged the bloodebrain barrier to permit
abnormal transit of peripheral apoE into brain parenchyma.The American Journal of Pathology - ajp.amjpathol.orgThis also seems unlikely because previous studies have
shown that the bloodebrain barrier functions normally with
respect to albumin and immunoglobulin after 10-Gy mye-
loablative BMT in C57BL/6 mice.49 A potential explanation
consistent with these and others’ data are that increased
cerebral apoE in APOE3/3 recipients involves paracrine
interactions between engrafted microglia/monocytes and
resident cells, likely astrocytes, yielding increased tissue
apoE concentration. Although the precise mechanism for the
observed effects in transplanted mice remains unclear, it is
important to note that AD animals received selective beneﬁt
from adoptive transfer of APOE3/3 BM-derived cells, further
supporting this novel therapeutic strategy.
In contrast to apoE and albumin, Ab does cross the
bloodebrain barrier, and its degradation or transport by cells
outside the CNS forms the basis of the sink hypothesis for Ab
clearance.50 Because APOE3/3 recipients had relatively
increased differentiation to CD11bþ peripheral monocytes/
macrophages, a second possible explanation for our behav-
ioral and neuropathological outcomes following BMT is
enhanced peripheral clearance of Ab by the larger pool
of CD11bþ monocytes/macrophages, with the increased,915
Yang et alremotely mediated clearance of Ab responsible for reduced
neuroinﬂammation and improved behavioral performance.
To resolve the relative contribution of CNS versus peripheral
BMT-derived cells on our behavioral and neuropathological
endpoints, we are developing protocols for selective peri-
pheral or central engraftment.
APOE is associated, not only with AD, but also with
poorer clinical outcome in traumatic brain injury,51 cogni-
tion in Parkinson disease,52 multiple sclerosis,53 and other
neurological conditions, each of which has a signiﬁcant
inﬂammatory component. The data presented here suggest
that BMT-derived central and/or peripheral cells that
express APOE3 modulate behavior and neuropathological
changes in a mouse model of AD to a greater extent than
those expressing APOE4. Although the toxicity of mye-
loablative BMT limits its clinical application primarily to
malignancies, clinical trials for non-myeloablative BMT for
noncancerous disease, such as multiple sclerosis and dia-
betes, are currently used in outpatient settings and offer
hope that BMT might someday be adapted to be a potential
therapeutic option for chronic neurological diseases.
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